Drug Trial Radar · NCT07949669
A Study of HLX105 in Patients With Advanced or Metastatic Solid Tumors
Last checked: Nov 20, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
42
Planned (sponsor's estimate)
Start
Nov 30, 2026
Primary completion
Nov 30, 2027
Study completion Nov 30, 2028
Sponsor
- Lead sponsor
- Shanghai Henlius BiotechIndustry
- Sponsor type
- Industry
- First posted
- Nov 19, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label, first-in-human, Phase 1 study of HLX105, an anti-PD-1 antibody-IL-2 variant fusion protein, in adults with advanced or metastatic solid tumors that have progressed after standard treatment or for which no standard treatment is available. The main purpose is to evaluate the safety and tolerability of HLX105 and determine its maximum tolerated dose. The study will also assess how the body processes HLX105, whether antibodies against HLX105 develop, preliminary antitumor activity, and changes in immune cells and other biomarkers.
Conditions
- Solid Tumor (Phase I)
Interventions
HLX105Drug
HLX105 will be administered as an intravenous(IV) infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Dose-limiting toxicity (DLT)Time frame: The first 21 days starting with the first dose for participants dosed every 3 weeks, and the first 28 days starting with the first dose for participants dosed every 2 weeks.
- Maximum tolerated dose(MTD)Time frame: Up to approximately 2 years
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.